Alkermes (ALKS - Free Report) reported $287.6 million in revenue for the quarter ended March 2023, representing a year-over-year increase of 3.3%. EPS of $0.01 for the same period compares to $0.12 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $284.24 million, representing a surprise of +1.18%. The company delivered an EPS surprise of +133.33%, with the consensus EPS estimate being -$0.03.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $214.73 million versus the seven-analyst average estimate of $210.91 million. The reported number represents a year-over-year change of +25.4%.
- Revenues- Manufacturing and Royalty revenues: $72.86 million versus $71.41 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -30.7% change.
- Revenues- Research and development revenue: $0.01 million versus $0.41 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -94.4% change.
- Revenues- Key Commercial Product Revenues- LYBALVI: $38 million versus the four-analyst average estimate of $37.35 million.
- Revenues- Key Commercial Product Revenues- ARISTADA: $80.10 million versus the four-analyst average estimate of $79.42 million. The reported number represents a year-over-year change of +10.5%.
- Revenues- Key Commercial Product Revenues- VIVITROL: $96.70 million versus the four-analyst average estimate of $92.84 million. The reported number represents a year-over-year change of +13.9%.
View all Key Company Metrics for Alkermes here>>>Shares of Alkermes have returned +11.8% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s an American AI company that’s riding low right now, but it has rounded up clients like BMW, GE, Dell Computer, and Bosch. It has prospects for not just doubling but quadrupling in the year to come. Of course, all our picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Alkermes (ALKS - Free Report) reported $287.6 million in revenue for the quarter ended March 2023, representing a year-over-year increase of 3.3%. EPS of $0.01 for the same period compares to $0.12 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $284.24 million, representing a surprise of +1.18%. The company delivered an EPS surprise of +133.33%, with the consensus EPS estimate being -$0.03.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $214.73 million versus the seven-analyst average estimate of $210.91 million. The reported number represents a year-over-year change of +25.4%.
- Revenues- Manufacturing and Royalty revenues: $72.86 million versus $71.41 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -30.7% change.
- Revenues- Research and development revenue: $0.01 million versus $0.41 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -94.4% change.
- Revenues- Key Commercial Product Revenues- LYBALVI: $38 million versus the four-analyst average estimate of $37.35 million.
- Revenues- Key Commercial Product Revenues- ARISTADA: $80.10 million versus the four-analyst average estimate of $79.42 million. The reported number represents a year-over-year change of +10.5%.
- Revenues- Key Commercial Product Revenues- VIVITROL: $96.70 million versus the four-analyst average estimate of $92.84 million. The reported number represents a year-over-year change of +13.9%.
View all Key Company Metrics for Alkermes here>>>Shares of Alkermes have returned +11.8% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s an American AI company that’s riding low right now, but it has rounded up clients like BMW, GE, Dell Computer, and Bosch. It has prospects for not just doubling but quadrupling in the year to come. Of course, all our picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Get the latest research report on ALKS - FREE